Edition:
United States

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

4,588JPY
29 Jul 2016
Change (% chg)

¥55 (+1.21%)
Prev Close
¥4,533
Open
¥4,550
Day's High
¥4,594
Day's Low
¥4,492
Volume
3,141,900
Avg. Vol
2,691,822
52-wk High
¥6,609
52-wk Low
¥4,098

Latest Key Developments (Source: Significant Developments)

Fujifilm to bid for Takeda's research reagents unit - Nikkei
Thursday, 21 Jul 2016 01:18pm EDT 

: Fujifilm Holdings is set to make an offer for a laboratory chemicals unit of Takeda Pharmaceutical - Nikkei . Takeda is expected to put Wako Pure Chemical Industries on the chopping block as early as August - Nikkei .Among those interested in Wako Pure Chemical Business are Britain's Permira and other equity funds, as well as a major U.S. medical supplies Co - Nikkei.  Full Article

Takeda working with Nomura Holdings to sell chemicals unit - Bloomberg
Thursday, 21 Jul 2016 10:45am EDT 

:Takeda working with Nomura Holdings to sell chemicals unit, which could fetch more than $1 billion - Bloomberg, citing sources.  Full Article

TiGenix and Takeda enter into licensing agreement for ex-U.S. Rights to CX601
Tuesday, 5 Jul 2016 02:06am EDT 

TiGenix NV : Takeda <4502.T> and TiGenix enter into licensing agreement for ex-u.s. Rights to CX601 for treatment of complex perianal fistulas in patients with crohn's disease . TiGenix will receive an upfront cash payment of 25 million euros ($27.8 million) . TiGenix will be eligible to receive additional regulatory and sales milestone payments for up to a potential total of 355 million euros and double digit royalties on net sales by Takeda . First anticipated milestone payment is 15 million euros upon obtaining marketing authorization of CX601 in European Economic Area (EEA) .In addition, takeda will make an equity investment of 10 million euros in share capital of Tigenix within next 12 months.  Full Article

Takeda Pharmaceutical, Altos Therapeutics to develop Altos's ATC-1906
Friday, 1 Jul 2016 08:00am EDT 

Takeda Pharmaceutical Co Ltd <4502.T> : Co, Altos Therapeutics have entered into agreement to further development of Altos's proprietary compound ATC-1906 . Deal has option for co to acquire Altos from date of agreement, continuing for some time after completion of Phase 1 studies of ATC-1906 . As part of agreement, Takeda will provide Altos an upfront payment for option to acquire Altos . If Takeda elects to exercise option to buy Altos, Takeda would make an additional payment to acquire Altos . Altos would be eligible to receive additional payments linked to clinical development and achievement of key commercial milestones .No further details of agreement were disclosed.  Full Article

Takeda licenses global rights to Theravance Biopharma's TD-8954
Wednesday, 8 Jun 2016 08:00am EDT 

Theravance Biopharma Inc : Takeda Licenses Global Rights To Theravance Biopharma's Td-8954, a novel 5-HT4 agonist and motility agent for gastrointestinal motility disorders . Theravance biopharma inc says will receive an upfront cash payment of $15 million .Will be eligible to receive success based development and sales milestone payments as well as double digit royalties on worldwide net sales by takeda.  Full Article

Ultragenyx, Takeda enter into collaboration to develop, commercialize therapies for rare genetic diseases
Tuesday, 7 Jun 2016 07:00am EDT 

Ultragenyx Pharmaceutical Inc : Ultragenyx and Takeda enter into a collaboration to develop and commercialize therapies for rare genetic diseases . Ultragenyx pharmaceutical inc says to license and develop one or more product candidates from Takeda . Ultragenyx pharmaceutical inc says Takeda to make equity investment in Ultragenyx to fund development . Ultragenyx pharmaceutical inc says Takeda will invest up to $65 million in Ultragenyx in two tranches . A potential third equity investment by Takeda is contingent upon Ultragenyx achieving a specific development milestone on a second asset .Ultragenyx Pharmaceutical Inc says no additional financial details were disclosed.  Full Article

Takeda, Roivant Sciences launch Myovant Sciences to develop therapeutics for women's health, prostate cancer
Monday, 6 Jun 2016 07:00am EDT 

Takeda Pharmaceutical Co <4502.T>: Roivant Sciences and Takeda launch Myovant Sciences to develop therapeutics for women's health and prostate cancer .Lynn Seely named president & Chief Executive Officer of Myovant Sciences Inc.  Full Article

EU health agency recommends approval of new hepatitis C drugs
Friday, 27 May 2016 07:21am EDT 

EU Medicines Agency : EU Medicines Agency recommendations for May 2016 . Recommends against approval of Takeda Pharmaceutical Co Ltd's <4502.T> ixazomib to treat multiple myeloma . Recommends approval of AstraZeneca Plc's saxagliptin/dapagliflozin to treat type 2 diabetes . Recommends approval of Takeda Pharmaceutical Co Ltd and Janssen's bortezomib to treat multiple myeloma . Recommends approval of Gilead Sciences Inc's sofosbuvir/velpatasvir to treat Hepatitis C .Recommends approval of Merck & Co's Elbasvir / grazoprevir to treat Hepatitis C.  Full Article

Valeant received joint takeover approach from Takeda, TPG before Joseph Papa became CEO - source
Thursday, 26 May 2016 11:00pm EDT 

: Valeant received joint takeover approach from Takeda, TPG a few weeks before Joseph Papa became CEO - Source Further company coverage: [VRX.TO] (Bengaluru Newsroom: +1 646 223 8780).  Full Article

Valeant approached by earlier rejected Takeda, TPG for takeover-CNBC
Thursday, 26 May 2016 07:22pm EDT 

: Valeant received joint takeover approach from Takeda, TPG that it rejected this spring before hiring new CEO - CNBC, citing DJ .There are no current talks between Takeda, TPG And Valeant following rejection of takeover bid this spring - CNBC, citing DJ.  Full Article

Deals of the day- Mergers and acquisitions

July 26 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday: